This study investigates TCR-engineered T cells targeting KRAS mutations in solid tumors. The purpose of this study is to explore the effects of these engineered cells on tumors that cannot be surgically removed or have spread to other parts of the body.
The study evaluates the safety and initial effectiveness of these TCR-engineered T cells. It looks at how well the treatment works in managing the condition, focusing on its safety and potential anti-tumor activity.
- Who can participate: Adults aged 18 and older with advanced solid tumors, such as NSCLC or colorectal cancer, may participate. Participants must have a specific KRAS mutation and meet certain health criteria.
- Study details: Participants will receive TCR-engineered T cells as part of the study.
How understandable was the trial content above?
Hard to understand
Easy to understand